CIK 0001035354 · Non-accelerated filer<br>Smaller reporting company
Eloxx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ELOX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 841368850
- Phone
- 781-577-5300
- Business address
- P.O. BOX 274, ARLINGTON, MA, 02476
- Former names
- Sevion Therapeutics, Inc., SENESCO TECHNOLOGIES INC, NAVA LEISURE USA INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-10-16 | Aggarwal Sumit President and CEO | Grant or award · Stock Option (Right to Buy) | +42,790 | 42,790 | ||
| 2024-10-16 | Aggarwal Sumit President and CEO | Returned to the company · Stock Option (Right to Buy) | −35,580 | 0 | ||
| 2024-10-16 | Aggarwal Sumit President and CEO | Grant or award · Stock Option (Right to Buy) | +35,580 | 35,580 | ||
| 2024-10-16 | Aggarwal Sumit President and CEO | Returned to the company · Stock Option (Right to Buy) | −24,810 | 0 | ||
| 2024-10-16 | Aggarwal Sumit President and CEO | Grant or award · Stock Option (Right to Buy) | +24,810 | 24,810 | ||
| 2024-10-16 | Aggarwal Sumit President and CEO | Returned to the company · Stock Option (Right to Buy) | −68,700 | 0 | ||
| 2024-10-16 | Aggarwal Sumit President and CEO | Grant or award · Stock Option (Right to Buy) | +68,700 | 68,700 | ||
| 2024-10-16 | Walts Alan Edmund Director | Grant or award | +12,000 | 12,942 | ||
| 2024-10-16 | Androski Lindsay Director | Grant or award | +12,000 | 12,000 | ||
| 2024-10-16 | Rubin Steven D Director | Grant or award | +12,000 | 12,000 | ||
| 2024-10-16 | Aggarwal Sumit PRESIDENT AND CEO | Grant or award | +165,000 | 169,930 | ||
| 2024-01-24 | Walts Alan Edmund Director | Grant or award · Restricted Stock Units | +7,500 | 7,500 | ||
| 2024-01-24 | Rubin Steven D Director | Grant or award · Restricted Stock Units | +7,500 | 7,500 | ||
| 2024-01-24 | Androski Lindsay Director | Grant or award · Restricted Stock Units | +7,500 | 7,500 | ||
| 2024-01-24 | Aggarwal Sumit PRESIDENT AND CEO | Grant or award · Restricted Stock Units | +60,000 | 60,000 | ||
| 2023-01-30 | Walts Alan Edmund Director | Grant or award · Stock Options (Right to Buy) | +2,859 | 2,859 | ||
| 2023-01-30 | Rubin Steven D Director | Grant or award · Stock Options (Right to Buy) | +2,859 | 2,859 | ||
| 2023-01-30 | Kariv Tomer Director | Grant or award · Stock Options (Right to Buy) | +2,859 | 2,859 | ||
| 2023-01-30 | Androski Lindsay Director | Grant or award · Stock Options (Right to Buy) | +2,859 | 2,859 | ||
| 2023-01-25 | Aggarwal Sumit PRESIDENT AND CEO | Grant or award · Stock Options (Right to Buy) | +68,700 | 68,700 |
Page 3 of 11 · 206 trades